Evidence map›Paper›PMID 15708886›Full record

Trial reportAnnals of the rheumatic diseases2005

Lamivudine is not effective in primary Sjögren's syndrome.

B Gescuk, A J Wu, J P Whitcher, T E Daniels, S Lund, K Fye, J C Davis

Open access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Is Sjögren's syndrome a retroviral disease?Arthritis research & therapy · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

B GescukClinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA.
A J Wu
J P Whitcher
T E Daniels
S Lund
K Fye
J C Davis
University of California, San Francisco · USSjögren’s Foundation · US

Funding

ANDROGEN AS ADJUNCT THERAPY IN RHEUMATOID ARTHRITISK23AR002113 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI DAVIS, JOHN C · 1999 to 2002
$439k
NIAMS NIH HHS 5K23/AR02113-02
6 · The paper itself

Abstract

backgroundRetroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome.

objectiveTo examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome.

methods16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment.

resultsTreatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores.

conclusionLamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.

Indexed as

AdultBiopsyDouble-Blind MethodFemaleHumansLamivudineLongitudinal StudiesMaleMiddle AgedReverse Transcriptase InhibitorsSalivary Glands, MinorSalivationSeverity of Illness IndexSjogren's SyndromeTearsTreatment FailureLamivudineReverse Transcriptase Inhibitors

Identifiers

PMID15708886
PMCPMC1755647
OpenAlexW2067721579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.